Posted Date: 3/7/2014

Cobra Biologics & BioCancell Announce Agreement for Promising Cancer Therapy

Cobra Biologics and BioCancell recently announced an agreement to manufacture BioCancell’s BC-821 cancer drug for clinical trials. BioCancell’s Phase I clinical trial for BC-821, scheduled to commence in 2015, is a continuity of the success of preclinical studies that examined the use of BC-821 as a treatment for several cancer indications, such as non-small-cell lung carcinoma, ovarian cancer, glioblastoma, and liver metastasis.

Cobra will provide GMP manufacture of BC-821 plasmid DNA, and fill and finish the product in accordance with aseptic manufacturing procedures before releasing it for clinical trials. Cobra’s experienced and expert team have a strong track record for producing non-GMP, high-quality, and GMP plasmid DNA for preclinical, clinical, and commercial supply, operating efficiently and consistently through a platform DNA process. Cobra’s DNA programs have full regulatory support from a dedicated Quality Assurance (QA) team.

BC-821 is a potential therapeutic product that penetrates cancerous cells and activates the synthesis of DTA under the control of H19 and /or P4 promoter of the target gene IGF2. Both H19 and P4-IGF2 transcription factors are expressed only in cancerous cells. This double-promoter method has the potential to reach a large patient population, as patients expressing either of the target genes will be treatable. An international patent application (PCT) for this product was filed by BioCancell in 2008.

“Cobra has been manufacturing plasmid therapeutics and DNA vaccines for more than 16 years, and I am delighted that we are able to announce this partnership with BioCancell. Our DNA platform process is based on Cobra’s pioneering heritage in gene therapy manufacturing and technology development,” said Peter Coleman, CEO Cobra Biologics.

Cobra Biologics is a leading international contract manufacturing organisation (CMO) of biologics and pharmaceuticals for clinical and commercial supply. Cobra has three GMP approved facilities, each with expertise tailored to serving customers around the world. For more information, visit www.cobrabio.com.

BioCancell is a biopharmaceuticals company that specializes in the development of targeted cancer therapies for the treatment of numerous types of cancer. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. For more information, visit www.biocancell.com.

Related Taxonomy
Popularity:
This record has been viewed 1189 times.





















- SHL


Click here to see the showcases


BIO Investor Forum
October 17-18, 2017
The Westin St. Francis, San Francisco, CA US
 
Partnership Opportunities in Drug Delivery (PODD)
October 19-20
Boston, MA

CPhI Worldwide
October 24-26
Frankfurt, Germany

Universe of Prefilled Syringes & Injection Devices Europe
November 7-8
Vienna, Austria

AAPS
November 12-17
San Diego, CA

Pre-Filled Syringes Europe
January 17-18, 2018
Copthorne Tara Hotel, London UK

Drug Delivery Partnerships
January 22-24 Palm Beach, FL

3rd Annual Drug Development Networking Summit
March 8, 2018  Hilton Hotel Parsippany NJ
 
PDA Annual Meeting
March 19-21 Orlando, FL
 
CPhI North America
April 24-26 Philadelphia, PA 
 
INTERPHEX
April 17-19 New York City
 
RDD (Respiratory Drug Delivery)
April 22-26 Tucson, AZ
 
BIO 2018
June 4-7 Boston, MA
 
Controlled Release Society Meeting
July 23-25 New York City
 
Universe of Prefilled Syringes & Injection Devices
October 8-9 Orlando, FL
 



Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions